CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 95 enrolled
Drug / intervention
Carboplatin and Vincristine +1 moredrug
Likely dose
Carboplatin and Vincristine 175 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02455245
NCT02455245Phase 3Active

A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

Alicia Lenzen·interventional·Posted May 27, 2015·Updated Nov 26, 2024

In Brief

A Phase 3 clinical trial evaluating Carboplatin and Vincristine and Carboplatin for Low Grade Glioma. Active but no longer recruiting, targeting 95 participants across 21 sites.

Detailed Summary

This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the use of carboplatin alone has promise of being just as effective for treating LGG as standard therapy. Additionally, this study will try to understand if treatment with carboplatin alone is associated with an improved quality of life for LGG patients and their families.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3ActiveOverdue
201520162017201820192020202120222023202420252026
First PostedMay 27, 2015
Enrollment StartMar 1, 2015
Primary CompletionAug 31, 2025
Study CompletionNov 30, 2025
TodayJul 2, 2026
Enrollment to primary: 10.5 yearsPosted 11.1 years ago

Interventions

Carboplatin and Vincristinedrug

Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV

Carboplatindrug

Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV